Open AccessOncostatin M decreases interleukin‐1 β secretion by human synovial fibroblasts and attenuates an acute inflammatory reaction in vivo
Author(s) -
Dumas Aline,
Lagarde Stéphanie,
Laflamme Cynthia,
Pouliot Marc
Publication year - 2012
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/j.1582-4934.2011.01412.x
Subject(s) - oncostatin m , in vivo , secretion , interleukin 6 , inflammation , chemistry , interleukin , immunology , medicine , cancer research , cytokine , biology , microbiology and biotechnology
Oncostatin M (OSM) is a pleiotropic cytokine of the IL‐6 family and displays both pro‐inflammatory and anti‐inflammatory activities. We studied the impact of OSM on the gene activation profile of human synovial cells, which play a central role in the progression of inflammatory responses in joints. In synovial cells stimulated with lipopolysaccharide and recombinant human granulocyte‐macrophage colony‐stimulating factor, recombinant human OSM and native OSM secreted by human granulocytes both reduced the gene expression and secretion of IL‐1β and CXCL8, but increased that of IL‐6 and CCL2. This impact on synovial cell activation was not obtained using IL‐6 or leukaemia inhibitory factor. Signal transducer and activator of transcription‐1 appeared to mediate the effects of OSM on stimulated human synovial fibroblasts. In the murine dorsal air pouch model of inflammation, OSM reduced the expression of the pro‐inflammatory cytokines IL‐1β and TNF‐α in lining tissues, and their presence in the cavity. These results as a whole suggest an anti‐inflammatory role for OSM, guiding inflammatory processes towards resolution.